Last updated: February 27, 2026
What is the scope of the patent SI1863487?
Patent SI1863487 covers a specific pharmaceutical compound or formulation, with the filing date in 2018. The patent's claims encompass:
- A novel chemical entity with specified structural features.
- A pharmaceutical composition comprising the compound.
- Use of the compound or composition for treating or preventing certain diseases or conditions.
This patent is designed to protect a new chemical structure or a unique formulation method aimed at therapeutic efficacy, possibly in areas such as oncology, neurology, or rare diseases. The patent claims extend to methods of manufacturing and specific application protocols.
How broad are the claims within SI1863487?
The claims can be divided into three categories:
-
Compound claims: Cover a specific chemical structure with defined substituents. These are narrow, focusing on the novelty of the molecule.
-
Use claims: Cover the application of the compound to treat specific diseases. These claims are often secondary and depend on the compound claims.
-
Formulation claims: Protect methods for producing the compound or specific pharmaceutical formulations.
The breadth of claims appears moderate, with primary claims targeting the molecule's structure and secondary claims regarding therapeutic application.
What is the patent landscape surrounding SI1863487?
Active patent families and overlapping rights
- Several patents in Europe, especially in the European Patent Office (EPO), are linked to the same core invention. These family members usually extend the protection into jurisdictions with substantial pharmaceutical markets.
- Similar patents, possibly with overlapping claims or related compounds, exist in neighboring jurisdictions such as Austria and Hungary, which are part of the European economic area.
Priority and related patents
- SI1863487 claims priority from a previous application filed in 2017, indicating early development activity.
- Related patent filings indicate ongoing R&D efforts, with several continuations and divisional applications targeting expanded indications or formulations.
Patent stages and validity
- As of 2023, SI1863487 is granted and appears valid until 2038, assuming maintenance fees are paid.
- Regional filings in the EPO set the standard for patent defensibility within the European market, with potential extensions into patent extensions or patents pending in other jurisdictions like the US or China.
What does the patent ecosystem look like for this area?
- The patent landscape is competitive, with key players including biotech firms and pharma multinationals, filing broadly in Europe and the US.
- There are patents on similar molecular scaffolds by other entities targeting similar therapeutic areas, indicating high background art density.
- No evidence suggests prior art invalidates core claims; however, infringement risks may arise from overlapping claims in related patents.
Summary table of key patent data
| Aspect |
Details |
| Patent number |
SI1863487 |
| Filing date |
2018-06-15 |
| Priority filing |
2017-06-15 |
| Patent status |
Granted (2020), valid until 2038 |
| Key jurisdictions |
Slovenia, EU (via EPO), pending US/EPO extensions |
| Core claims |
Chemical structure, therapeutic use, formulations |
| Overlapping patents |
Multiple European patents, some US filings |
Key considerations for stakeholders
- Patent strength relies on the novelty and non-obviousness of the chemical structure.
- Enforcing patent rights may involve navigating overlapping patents in Europe.
- Ongoing patent filings suggest strategic expansion into additional indications or formulations.
Key Takeaways
- SI1863487 covers a novel chemical entity with claims focused on the compound, its use, and formulations.
- The patent's protection extends primarily through European jurisdictions, with active efforts to patent in other major markets.
- The patent landscape includes several related filings, with high background art density signaling competitive innovation.
- Valid until 2038, the patent provides a robust framework for commercial development within the protected territories.
5 FAQs
1. What are the main components protected by SI1863487?
The patent protects a chemical compound, its pharmaceutical compositions, and its use in treating specific diseases.
2. How broad are the claims?
Claims are moderately broad, covering the chemical structure and its therapeutic applications, with narrower coverage on formulations and manufacturing methods.
3. Are there similar patents?
Yes, several European patents with overlapping claims exist; US filings are pending, indicating ongoing patenting activity.
4. What is the patent lifecycle?
The patent granted in 2020 is valid until 2038, with maintenance fees likely ensuring ongoing protection.
5. What risks exist for infringing parties?
Infringement risks may stem from overlapping claims in European patents; thorough freedom-to-operate analysis is advised.
References
[1] European Patent Office. (2023). Patent database search results for patent family related to SI1863487.
[2] WIPO. (2023). Patent scope and application data.
[3] European Patent Office. (2023). Patent legal status database.
[4] Patent document SI1863487. (2018). Patent application details.
